The Mind and Gut Interactions Cohort Study

Summary

Many Canadians experience gastrointestinal (GI) symptoms, such as abdominal pain, diarrhea, and/or constipation. These symptoms are often a result of GI disorders, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The causes of IBD and IBS are unknown and current available treatments are no effective for everyone. The goal of our study is to improve the treatment of IBD and IBS. This will be done by learning more about gut bacteria, diet, and GI symptoms of those suffering from IBD and IBS, compared to healthy people. We are also interested in understanding how stress and mental health issues, like depression and anxiety, can affect GI symptoms.

Eligibility

Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 4 to 18

Inclusion criteria:

1. Lower Age Limit: 4
2. Upper Age Limit: 18
3. Male, Female, or Intersex
4. Your child may be eligible to participate in this study if:
- they have been diagnosed by a physician with Inflammatory Bowel Disease (IBD), including ulcerative colitis or Crohn's disease

Exclusion criteria:

1. Under 4 years of age
2. Past gastrointestinal bypass surgery or major bowel resection unrelated to Crohn's disease.
3. Major concurrent illness such as chronic kidney disease, chronic liver disease other than primary sclerosing cholangitis, chronic immune disease unrelated to IBD.
4. Active eating disorder, such as anorexia nervosa or bulimia.
5. Cannot communicate in either English or French.

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

Amy Lee Wing Ngok, Study Coordinator

Principal investigator:

Jennifer deBruyn

Clinical trial:

No

REB-ID:

REB19-2045